Spain Anti-Rheumatic Drug Market Size, Share, and COVID-19 Impact Analysis, By Type of Disease (Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, and Others), By Drug Class (Disease-modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, JAK inhibitor, and Others), By Sales Channel (Prescription and Over-the-counter (OTC)), and Spain Anti-Rheumatic Drug Market Insights, Industry Trend, Forecasts to 2033

Spain Anti-Rheumatic Drug Market Insights Forecasts to 2033

• The Spain Anti-Rheumatic Drug Market Size Was Valued at USD 3611.0 Million in 2023.
• The Spain Anti-Rheumatic Drug Market Size is Growing at a CAGR of 2.09% from 2023 to 2033
• The Spain Anti-Rheumatic Drug Market Size is Expected to reach USD 4439.0 Million by 2033

The Spain Anti-Rheumatic Drug Market Size is Anticipated to Exceed USD 4439.0 Million by 2033, Growing at a CAGR of 2.09% from 2023 to 2033. The increasing incidence of rheumatic diseases and increasing old-age population are driving the growth of the anti-rheumatic drug market in the Spain.     

Market Overview

The anti-rheumatic drug market refers to the industry encompassing medications that are used for treating inflammatory conditions such as rheumatism and arthritis, which includes both non-steroidal and steroidal anti-rheumatics. Anti-rheumatic drugs are specifically disease-modifying antirheumatic drugs (DMARDs) treating autoimmune conditions such as rheumatoid arthritis, by modifying the course of the disease and reducing inflammation. The increasing prevalence of rheumatic diseases along with the growing aging populations are escalating the market demand for anti-rheumatic drug. Further, the growing awareness about rheumatoid arthritis and its early treatment intervention, as well as the emergence of precision medicine, aid in driving the growth in the anti-rheumatic drugs market. The development in the field of biosimilars, which are cost-effective alternatives to biologic DMARDs as well as novel biologics, is providing growth opportunities in the anti-rheumatic drug market.

Report Coverage

This research report categorizes the market for the Spain anti-rheumatic drug market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Spain anti-rheumatic drug market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Spain anti-rheumatic drug market.

Driving Factors

The growing aging population is expected to drive the rheumatic drug market demand as rheumatoid arthritis is the most common age-associated disease. Investment in drugs and healthcare with the growing hospital infrastructures contributes to driving market growth. The estimated prevalence of rheumatoid arthritis (RA) in the general adult population is 0.82%, with an estimated 220,000 to 430,000 people aged 20 or older having RA. Furthermore, the advancement in biologics and targeted therapies along with the upsurging patient awareness, are propelling the market growth.

Restraining Factors

The increased cost of biologics anti-rheumatic drugs, as well as side effects associated with medications, are restraining the market. Further, the complexities in drug manufacturing and regulatory requirements for drug approvals are challenging the market growth.

Market Segmentation

The Spain anti-rheumatic drug market share is classified into drug class and sales channel.

• The disease-modifying anti-rheumatic drugs segment dominated the market with the largest market share in 2023 and is expected to grow at a significant CAGR during the predicted timeframe.

The Spain anti-rheumatic drug market is segmented by drug class into disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, JAK inhibitor, and others. Among these, the disease-modifying anti-rheumatic drugs segment dominated the market with the largest market share in 2023 and is expected to grow at a significant CAGR during the predicted timeframe. Disease-modifying anti-rheumatic drugs are used in people with rheumatoid arthritis for decreasing pain and inflammation, reducing or prevent joint damage, and preserving the structure and function of the joints. The prevalence of rheumatid arthritis and increased awareness about the drugs are contributing to driving the market demand.

• The prescription segment dominated the market with the largest market share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

The Spain anti-rheumatic drug market is segmented by sales channel into prescription and over-the-counter (OTC). Among these, the prescription segment dominated the market with the largest market share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. Prescription drug usage requires professional medical guidance for safe and effective use. The increasing number of specialized hospitals and the need for specialized care from medical professionals are propelling the market in the prescription segment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Spain anti-rheumatic drug market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AbbVie Inc.
• Amget Inc.
• Johnson and Johnson
• Pfizer Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Eli Lilly and Company
• Novartis AG
• Celgene Corporation (Bristol-Myers Squibb)
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Spain, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Spain anti-rheumatic drug market based on the below-mentioned segments:

Spain Anti-Rheumatic Drug Market, By Drug Class

• Disease-Modifying Anti-Rheumatic Drugs
• Nonsteroidal Anti-Inflammatory Drugs
• Corticosteroids
• JAK Inhibitor
• Others

Spain Anti-Rheumatic Drug Market, By Sales Channel

• Prescription
• Over-The-Counter (OTC)